Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 7/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.44 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.44 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 2/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17055716 | 0.84 | CYP19A1 (0.45) | FGFR1CYP1A2HTTALDH1A1SRC | |
| SCHEMBL1150276 | 0.77 | HPGD (0.49) | FGFR1CYP1A2HTTALDH1A1HPGD | |
| SCHEMBL13993884 | 0.75 | FGFR1 (0.76) | FGFR1HTTALDH1A1HPGDMAPK1 | |
| SCHEMBL7924961 | 0.73 | CYP1A2 (0.42) | CYP1A2ALDH1A1ADORA3ADORA2AADORA1 | |
| SCHEMBL30662366 | 0.72 | RPS6KA5 (0.51) | FGFR1CYP1A2HTTALDH1A1HPGD | |
| SCHEMBL16302846 | 0.72 | CYP1A2 (0.37) | CYP1A2ALDH1A1HPGDADORA3ADORA2A | |
| SCHEMBL12140729 | 0.72 | MEN1 (0.51) | CYP1A2ALDH1A1HPGDADORA3ADORA2A | |
| SCHEMBL12140739 | 0.72 | MEN1 (0.51) | CYP1A2ALDH1A1HPGDADORA3ADORA2A | |
| SCHEMBL12140738 | 0.72 | MEN1 (0.51) | CYP1A2ALDH1A1HPGDADORA3ADORA2A | |
| SCHEMBL16302854 | 0.72 | CYP1A2 (0.41) | CYP1A2ALDH1A1HPGDADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580813-B2 | Cyclic azaindole-3-carboxamides, their preparation and their use as pharmaceuticals | SANOFI (FR) | 2013-11-12 | — | — | US | disclosed |
| EP-2240482-B1 | CYCLIC AZAINDOLE-3-CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2013-07-17 | — | — | EP | disclosed |
| US-20110039861-A1 | CYCLIC AZAINDOLE-3-CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2011-02-17 | — | — | US | disclosed |
| EP-2240482-A1 | CYCLIC AZAINDOLE-3-CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2010-10-20 | — | — | EP | disclosed |
| WO-2009095162-A1 | CYCLIC AZAINDOLE-3-CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2009-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039861-A1 | CYCLIC AZAINDOLE-3-CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | REN, PM20D2, CDK20 | FGFR1 2590/4885CYP1A2 117/4885HTT 3555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.